蛋白激酶C定位的高特异性调节剂：在心力衰竭中的应用
Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure.
作者信息
Qvit Nir, Mochly-Rosen Daria
机构信息
Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford CA 94305-5174.
出版信息
Drug Discov Today Dis Mech. 2010 Summer;7(2):e87-e93. doi: 10.1016/j.ddmec.2010.07.001.
Abstract
Heart failure (HF) in which the blood supply does not match the body's needs, affects 10% of the population over 65 years old. The protein kinase C (PKC) family of kinases has a key role in normal and disease states. Here we discuss the role of PKC in HF and focus on the use of specific PKC regulators to identify the mechanism leading to this Pathology and potential leads for therapeutics.
摘要
心力衰竭（HF）是指血液供应无法满足身体需求的一种病症，影响着10%的65岁以上人群。蛋白激酶C（PKC）激酶家族在正常和疾病状态中都起着关键作用。在此，我们将探讨PKC在HF中的作用，并着重关注使用特定的PKC调节剂来确定导致这种病理状况的机制以及潜在的治疗线索。
相似文献
1
Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure.蛋白激酶C定位的高特异性调节剂：在心力衰竭中的应用
Drug Discov Today Dis Mech. 2010 Summer;7(2):e87-e93. doi: 10.1016/j.ddmec.2010.07.001.
2
Protein kinase C and cardiac dysfunction: a review.蛋白激酶 C 与心功能障碍：综述
Heart Fail Rev. 2017 Nov;22(6):843-859. doi: 10.1007/s10741-017-9634-3.
3
PKC isozymes in chronic cardiac disease: possible therapeutic targets?慢性心脏疾病中的蛋白激酶C同工酶：可能的治疗靶点？
Annu Rev Pharmacol Toxicol. 2008;48:569-99. doi: 10.1146/annurev.pharmtox.48.121806.154902.
4
Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression.蛋白激酶C通过调节半乳糖凝集素-3的表达促进心脏纤维化和心力衰竭。
Biochim Biophys Acta. 2015 Feb;1853(2):513-21. doi: 10.1016/j.bbamcr.2014.12.001. Epub 2014 Dec 7.
5
Pharmacological Protein Kinase C Modulators Reveal a Pro-hypertrophic Role for Novel Protein Kinase C Isoforms in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.药理蛋白激酶C调节剂揭示新型蛋白激酶C亚型在人诱导多能干细胞衍生心肌细胞中的促肥大作用。
Front Pharmacol. 2021 Jan 20;11:553852. doi: 10.3389/fphar.2020.553852. eCollection 2020.
6
The role of protein kinase C-mediated phosphorylation of sarcomeric proteins in the heart-detrimental or beneficial?蛋白激酶C介导的肌节蛋白磷酸化在心脏中起有害还是有益作用？
Biophys Rev. 2011 Sep;3(3):107. doi: 10.1007/s12551-011-0050-y. Epub 2011 Jun 28.
7
The role of protein kinase C activation and the vascular complications of diabetes.蛋白激酶C激活的作用与糖尿病的血管并发症
Pharmacol Res. 2007 Jun;55(6):498-510. doi: 10.1016/j.phrs.2007.04.016. Epub 2007 May 5.
8
Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy.遗传性心肌病所致心力衰竭中蛋白激酶A和蛋白激酶C水平的改变。
Can J Cardiol. 1999 Jun;15(6):683-90.
9
Protein kinase C in heart failure: a therapeutic target?心力衰竭中的蛋白激酶C：一个治疗靶点？
Cardiovasc Res. 2009 May 1;82(2):229-39. doi: 10.1093/cvr/cvp001. Epub 2009 Jan 24.
10
PKC and PKN in heart disease.蛋白激酶 C 和 PKN 在心脏病中的作用。
J Mol Cell Cardiol. 2019 Mar;128:212-226. doi: 10.1016/j.yjmcc.2019.01.029. Epub 2019 Feb 8.
引用本文的文献
1
Special Issue: "Molecular Dynamics Simulations and Structural Analysis of Protein Domains".特刊：“蛋白质结构域的分子动力学模拟与结构分析”
Int J Mol Sci. 2024 Oct 8;25(19):10793. doi: 10.3390/ijms251910793.
2
An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.蛋白激酶作为治疗靶点的最新研究进展——第一部分：蛋白激酶 C 的激活及其在癌症和心血管疾病中的作用。
Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600.
3
An Update on Protein Kinases as Therapeutic Targets-Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein-Protein Interactions.蛋白激酶作为治疗靶点的最新研究进展——第二部分：靶向蛋白-蛋白相互作用的别构蛋白激酶 C 调节剂肽。
Int J Mol Sci. 2023 Dec 15;24(24):17504. doi: 10.3390/ijms242417504.
4
A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.一种选择性的线粒体融合蛋白 1-βIIPKC 结合抑制剂可改善大鼠心力衰竭的预后。
Nat Commun. 2019 Jan 18;10(1):329. doi: 10.1038/s41467-018-08276-6.
5
Sirtuin 1 represses PKC-ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy.Sirtuin 1 通过调节心脏肥大中乙酰化和磷酸化的相互作用来抑制 PKC-ζ 的活性。
Br J Pharmacol. 2019 Feb;176(3):416-435. doi: 10.1111/bph.14538. Epub 2018 Dec 9.
6
Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.血管平滑肌收缩的演变机制突出了血管疾病的关键靶点。
Biochem Pharmacol. 2018 Jul;153:91-122. doi: 10.1016/j.bcp.2018.02.012. Epub 2018 Feb 13.
7
Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.蛋白激酶C作为血管平滑肌功能的调节因子及血管疾病的潜在靶点
Adv Pharmacol. 2017;78:203-301. doi: 10.1016/bs.apha.2016.06.002. Epub 2016 Jul 18.
8
Peptides and peptidomimetics as regulators of protein-protein interactions.作为蛋白质-蛋白质相互作用调节剂的肽和拟肽
Curr Opin Struct Biol. 2017 Jun;44:59-66. doi: 10.1016/j.sbi.2016.12.009. Epub 2017 Jan 4.
9
Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.工程化底物特异性的 PKCδ 拮抗剂以增强心脏治疗效果。
Angew Chem Int Ed Engl. 2016 Dec 12;55(50):15672-15679. doi: 10.1002/anie.201605429. Epub 2016 Nov 17.
10
PKCε mediates resistin-induced NADPH oxidase activation and inflammation leading to smooth muscle cell dysfunction and intimal hyperplasia.蛋白激酶Cε（PKCε）介导抵抗素诱导的NADPH氧化酶激活和炎症反应，进而导致平滑肌细胞功能障碍和内膜增生。
Atherosclerosis. 2016 Oct;253:29-37. doi: 10.1016/j.atherosclerosis.2016.08.015. Epub 2016 Aug 20.
本文引用的文献
1
Rationally designed peptide regulators of protein kinase C.蛋白激酶C的合理设计肽调节剂
Trends Endocrinol Metab. 2009 Jan;20(1):25-33. doi: 10.1016/j.tem.2008.10.002. Epub 2008 Dec 4.
2
Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.肥大细胞与ε蛋白激酶C：在高血压性心力衰竭心脏重塑中的作用
J Mol Cell Cardiol. 2008 Dec;45(6):779-86. doi: 10.1016/j.yjmcc.2008.08.009. Epub 2008 Sep 4.
3
Null mutations in human and mouse orthologs frequently result in different phenotypes.人类和小鼠直系同源基因中的无效突变常常导致不同的表型。
Proc Natl Acad Sci U S A. 2008 May 13;105(19):6987-92. doi: 10.1073/pnas.0800387105. Epub 2008 May 5.
4
Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure.ε-蛋白激酶C的药理学抑制作用可减轻高血压性心力衰竭中的心脏纤维化和功能障碍。
Hypertension. 2008 Jun;51(6):1565-9. doi: 10.1161/HYPERTENSIONAHA.107.109637. Epub 2008 Apr 14.
5
The PKCdelta -Abl complex communicates ER stress to the mitochondria - an essential step in subsequent apoptosis.蛋白激酶Cδ-阿卜林复合物将内质网应激传递至线粒体，这是随后细胞凋亡过程中的关键一步。
J Cell Sci. 2008 Mar 15;121(Pt 6):804-13. doi: 10.1242/jcs.024653. Epub 2008 Feb 19.
6
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.冠状动脉内注射KAI-9803作为急性ST段抬高型心肌梗死直接经皮冠状动脉介入治疗的辅助手段。
Circulation. 2008 Feb 19;117(7):886-96. doi: 10.1161/CIRCULATIONAHA.107.759167. Epub 2008 Feb 4.
7
The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury.蛋白激酶Cδ和ε同工酶在心肌缺血/再灌注损伤调节中的作用。
Biochem Soc Trans. 2007 Nov;35(Pt 5):1040-2. doi: 10.1042/BST0351040.
8
PKC isozymes in chronic cardiac disease: possible therapeutic targets?慢性心脏疾病中的蛋白激酶C同工酶：可能的治疗靶点？
Annu Rev Pharmacol Toxicol. 2008;48:569-99. doi: 10.1146/annurev.pharmtox.48.121806.154902.
9
Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model.ε蛋白激酶C的药理学抑制作用可抑制小鼠心脏移植模型中的慢性炎症。
J Mol Cell Cardiol. 2007 Oct;43(4):517-22. doi: 10.1016/j.yjmcc.2007.06.003. Epub 2007 Jun 21.
10
Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy.人类心脏中的蛋白激酶C：主动脉瓣狭窄或扩张型心肌病中各亚型的差异调节
Mol Cell Biochem. 2007 Nov;305(1-2):103-11. doi: 10.1007/s11010-007-9533-3. Epub 2007 Jun 27.
Zotero 插件